秒速时时彩

Winning the battle • Starting a new journey in flu control

Posted: November 26, 2019 Posted by: CSPC


Qixiao® Shenzhen Launch Conference Successfully Held

"Which rains early, and autumn gradually enters winter." Early winter means the arrival of the flu season. In order to better prevent and control the flu, CSPC actively responded to the call and was sponsored by the Shenzhen Medical Association on November 24. During the "Shenzhen Respiratory Disease Summit Forum 2019" conference hosted by Shenzhen People's Hospital and Shenzhen Institute of Respiratory Diseases, the launch conference of Shenzhen Qixiao® (Abidol Hydrochloride Tablets) was solemnly held.


WeChat screenshot_20191126173001.png


This meeting is honored to invite Professor Chen Rongchang, Chairman of the Chinese Medical Association Respiratory Branch, Professor Cai Shaoxi, Chairman of the Respiratory Branch of the Guangdong Medical Association, as the chairman of the conference, and Professor Tao Weihua, Vice President of the Respiratory Branch of the Shenzhen Medical Association, as speakers. Covering a total of 150 experts in the respiratory field in Guangdong and Hainan, Ms. Chu Cangli, general manager of Ainuo Sales Company of CSPC, attended the meeting and witnessed the listing of Qixiao® of CSPC.

At the beginning of the market launch, Professor Cai Shaoxi pointed out that with the continuous evolution and evolution of influenza viruses, influenza prevention and control are facing serious challenges. The main challenge is the lack of antiviral drugs. Clinically, many antiflu drugs with different mechanisms of action are urgently needed. . Today we ushered in a new type of weapon, the hemagglutinin inhibitor abidol hydrochloride tablet (Qixiao®). Its appearance has given us new hope in the field of anti-flu!


WeChat screenshot_20191126172939.png


Ms. Chu Cangli, General Manager of CSPC Aino Sales Co., Ltd. expressed her gratitude to the attending experts and introduced the history of CSPC's red development and Abidol. She mentioned that Abidol has entered China's 2019 National Medical Insurance Catalogue and The 2019 National Health Commission's "Influenza Diagnosis and Treatment Program" hopes that experts can give more guidance and help to Abidol's clinical research and academic promotion after listing.


WeChat screenshot_20191126172917.png


Academic Session

Professor Tao Weihua, Director of Respiratory Critical Care at Shenzhen People's Hospital, brought us the "Clinical Application of Anti-Influenza Drugs". In the report, Professor Tao proposed that influenza should be paid enough attention and explained the difference between Abidol and other types of anti-flu drugs: Abidol hydrochloride is the only hemagglutinin inhibitor, which has a more advanced mechanism of action than neuraminidase inhibitors, preventing virus replication from the source; and Abidol can also induce the production of interferon Improve the body's immunity, and the dual mechanisms work together to achieve a significant effect. At the same time, Professor Tao highly recognizes the characteristics of Abidol's broad-spectrum antiviral and believes that Qixiao® will surely play a "qi" effect on the future anti-flu battlefield!


WeChat screenshot_20191126173013.png


Meeting summary

At the end of the meeting, Professor Chen Rongchang said that the current effective flu treatment drugs are severely lacking, and neuraminidase inhibitors are gradually showing resistance. This meeting gave us a new hope for anti-flu-Qixiao® (AHC Bodor film), I believe that this powerful new weapon will definitely shine in the flu prevention and victory, help us win in the future battle with the flu, and finally, thank the CSPC Group for bringing us A new choice, let us start a new journey of flu prevention together!

WeChat screenshot_20191126173023.png